Gilead Signs Generics Pact For Sovaldi In Developing Countries
This article was originally published in The Pink Sheet Daily
The deal will make Gilead’s expensive hepatitis C treatment sofosbuvir affordable for patients living in developing countries, more than half of the total global infected patient population.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.